
Person deep dive
Beth Seidenberg
#23 2026 Strebulaev–Jackson Venture Ranking, emerging firms
Beth Seidenberg was chief medical officer at Amgen and a Kleiner Perkins partner from 2005, then founded Westlake Village BioPartners in 2018 with $320M. At Kleiner she incubated or sat on the boards of Atara and Epizyme, which both listed on Nasdaq.
Track record
Investments Beth Seidenberg is best known for, with what became of them.
EpizymeIncubated or board member at Kleiner PerkinsListed on Nasdaq in 2013; acquired by Ipsen in 2022
Atara BiotherapeuticsIncubated or board member at Kleiner PerkinsListed on Nasdaq in 2014
ACELYRINFirm-backedListed on Nasdaq in 2023
Kate TherapeuticsFirm-backedAcquired by Novartis for up to $1.1B in 2024
Westlake Village BioPartners
FirmWestlake Village BioPartners
Founded2018
Based inLos Angeles
Funds$320M first fund in 2018; $450M Fund III in 2023; about $1.3B raised since 2018
FocusBuilding and backing early-stage life sciences companies
Career
- Before 2005Served as chief medical officer and head of global development at Amgen.
- 2005Became a general partner at Kleiner Perkins.
- 2018Launched Westlake Village BioPartners with $320M.
- 2023Closed Westlake's $450M third fund.
Sources: TechCrunch: Beth Seidenberg raises $320M (2018) · Venture Capital Journal: Westlake collects $450M · Dealroom: Westlake Village BioPartners. Rank: 2026 Strebulaev–Jackson Venture Ranking.
Currently
Active roles, board seats and partnerships.

Westlake Village BioPartners